Buprenorphine Hydrochloride/Granisetron

盐酸丁丙诺啡/格拉司琼

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBuprenorphine Hydrochloride/Granisetron
Drug Alias NameGranisetron+Buprenorphine格拉司琼/丁丙诺啡Granisetron/Buprenorphine格拉司琼+丁丙诺啡丁丙诺啡+格拉司琼 +[8] 
ClassificationSmall molecules
Mechanisms of ActionMu opioid receptor agonistsSerotonin 3 (5-HT3) receptor antagonistsKappa opioid receptor antagonists
TargetsMu opioid receptorKappa opioid receptorSerotonin 3 (5-HT3) receptor
Therapy Area/IndicationsPostoperative Nausea and VomitingPain, Postoperative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Buprenorphine HydrochlorideGranisetron
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCamurus Ab
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBraeburn PharmaCamurus Ab
Active IndicationsN/A
Inactive IndicationsPostoperative Nausea and VomitingPain, Postoperative

Other Information

ATC CodeN/A
Related LinksN/A